Clinical Trials Logo

Clinical Trial Summary

Angioedema is a disease characterized by the appearance of self-limiting edema that last 1-5 days and affect the subcutaneous tissue and/or gastrointestinal and oropharyngeal mucosa. In this last location edema can be lethal causing asphyxia, in all other cases full recovery is complete. Attacks can appear as part of the syndrome urticaria angioedema and can be of allergic origin. But there is a group of non-allergic angioedema that occur without hives and can be either hereditary or acquired. These angioedema are identified in some cases on the basis of etiology, in others are identified by the mediator and an overall classification of these forms of angioedema was published in 2014 as a result of a consent conference organized by the proponents of this registry. Being these forms of angioedema rare, there are not significative case studies inclusive of a high number of patients. This registry aims to collect in a single place a high number of subjects with recurring angioedema and without urticaria.


Clinical Trial Description

The Grenoble center is the registry coordinator at the national level. It will contract directly with the Cloud R Company and will be in charge of coordinating the associated centers. It will therefore send the necessary documents for the good execution of the study, will ask each center to respect the current French regulatory, will organize and finance the set-up of the register in the associated centers. The coordinating center will also centralize requests for data, publications or creation of additional eCRF pages of associated centers. It will be able to organize a national scientific committee every 6 months. It will thus be the link between the French centers, the scientific committee of the registry and the company Cloud R. The coordinating center will also be responsible for enter and reliability of patient data from it center, as well as the associated centers. Role of associated centers Associated Centers will be responsible for capturing and data reliability of their patients in eCRF, they will also create a personal account for each patient so that it can download the application "cloud R HAE carnet de suivi". Investigators referent patient will have validated at each visit or after contact with the patient crisis returned to the patient via it electronic diary. Associated Centers will keep informed twice a year the coordinator center of the state of inclusions in the register. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03845946
Study type Observational [Patient Registry]
Source University Hospital, Grenoble
Contact laurence bouilelt, MD, PhD
Phone +33476765565
Email lbouillet@chu-grenoble.fr
Status Recruiting
Phase
Start date September 1, 2018
Completion date September 1, 2028

See also
  Status Clinical Trial Phase
Not yet recruiting NCT00163839 - The Efficacy of a Pseudoallergen-Free Diet in the Treatment of Chronic Idiopathic Urticaria and/or Angioedema N/A
Recruiting NCT04597944 - Lanadelumab in Bradykinin Angioedema
Completed NCT00876369 - Vitamin D Levels in Subjects With Chronic Urticaria and Angioedema
Completed NCT02833675 - Determination of Specific Biomarkers of Angioneurotic Crisis N/A
Completed NCT06096077 - Evaluation of Tranexamic Acid for Angiotensin-converting Enzyme Inhibitor-induced Angioedema in the Emergency Department
Completed NCT00125541 - C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema Phase 2/Phase 3
Completed NCT01371877 - The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment N/A
Completed NCT04206605 - A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) Phase 3
Unknown status NCT01036659 - Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Phase 2
Recruiting NCT05578417 - A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada
Recruiting NCT05936567 - Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria Phase 2
Recruiting NCT04334031 - Deployment o the Multidisciplinary Prospective Cohort Imminent N/A
Completed NCT03240991 - Study of Clinical, Biological Characteristics and Quality of Life of Patients With Hereditary or Acquired Non Drug-induced Bradykinin-mediated Angioedema, Monitored in Besançon's Partner Site Reference Center for Studies of Kinin-mediated Angioedema (CREAK)
Completed NCT01723072 - Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy Phase 3
Completed NCT00385372 - Significance of an Elimination and Provocation Diet in Patients With Chronic Urticaria N/A
Completed NCT00004694 - Study of Heparin Prophylaxis of Hereditary Angioedema Exacerbations N/A
Not yet recruiting NCT06210698 - Angioedema Biomarker Research Study
Terminated NCT04128371 - Mepolizumab in Episodic Angioedema With Eosinophilia Phase 2
Completed NCT04444895 - A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor Phase 3
Completed NCT00125151 - C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema Phase 3